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Abstract
Background: Respiratory syncytial virus (RSV) is an important pathogen that can cause severe
illness in infants and young children. In this study, we assessed whether data on RSV collected by
the European Influenza Surveillance Scheme (EISS) could be used to build an RSV surveillance
system in Europe.
Methods: Influenza and RSV data for the 2002–2003 winter season were analysed for England,
France, the Netherlands and Scotland. Data from sentinel physician networks and other sources,
mainly hospitals, were collected. Respiratory specimens were tested for influenza and RSV mainly
by virus culture and polymerase chain reaction amplification.
Results: Data on RSV were entered timely into the EISS database. RSV contributed noticeably to
influenza-like illness: in England sentinel RSV detections were common in all age groups, but
particularly in young children with 20 (40.8%) of the total number of sentinel swabs testing positive
for RSV. Scotland and France also reported the highest percentages of RSV detections in the 0–4
year age group, respectively 10.3% (N = 29) and 12.2% (N = 426). In the Netherlands, RSV was
detected in one person aged over 65 years.
Conclusion: We recommend that respiratory specimens collected in influenza surveillance are
also tested systematically for RSV and emphasize the use of both community derived data and data
from hospitals for RSV surveillance. RSV data from the EISS have been entered in a timely manner
and we consider that the EISS model can be used to develop an RSV surveillance system equivalent
to the influenza surveillance in Europe.
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Background
Respiratory syncytial virus (RSV) is the most important
viral agent causing severe respiratory disease in infants
and young children [1]. Although infrequently recog-
nised, RSV infection is common in adults and sometimes
causes severe illness especially in the elderly [2,3]. RSV
infection presents with similar clinical symptoms to other
respiratory viral infections, including influenza [4,5].
Influenza is associated with increased general practice
consultation rates [6], increased hospital admissions [7]
and excess deaths [7,8]. RSV and influenza viruses fre-
quently co-circulate around the same time of the year
making it difficult to estimate their separate clinical
impacts [9]. The contribution of RSV to influenza-like ill-
ness needs to be assessed if this is to be used as a clinical
endpoint for evaluating influenza vaccine effectiveness
[10,11].
Advances in the development of RSV vaccines [12] has
prompted a need for research into the societal and eco-
nomic impact of RSV infection in order to make sensible
decisions about their potential use. So far, prevention of
severe RSV-associated bronchiolitis has only been
achieved in high-risk infants by passive administration of
the humanized monoclonal antibody palivizumab [13].
A timely RSV surveillance system could be valuable in
optimizing the use of palivizumab by increasing its effi-
ciency and reducing costs [14] as doctors would become
aware of the circulation of the virus and probable cause of
illness in high-risk infants.
Monitoring influenza activity has been coordinated by the
European Influenza Surveillance Scheme (EISS) since
1996. EISS is one of the Designated Surveillance Networks
established to monitor infectious diseases in the Euro-
pean Union [15]. The surveillance is performed by senti-
nel primary care physicians and is based on an integrated
clinical and virological surveillance model [16,17]. In
addition to the sentinel surveillance, results on specimens
obtained from other sources (mostly hospitals) are also
reported. Currently, no integrated European surveillance
such as the EISS is in place for RSV, although RSV surveil-
lance initiatives have been reported from several EU Mem-
ber States (Germany, the Netherlands, France, United
Kingdom).
We aimed to assess whether data already collected within
EISS could be used to build an RSV surveillance system in
Europe. We consider timeliness of RSV reports to EISS as
well as the collection of both sentinel and hospital-based
RSV data by age group important for RSV surveillance. We
analysed RSV and influenza virus reports in different age
groups and study populations in four European countries,
and we assessed whether RSV and influenza data were
reported in a timely manner into the EISS database.
Methods
Influenza and RSV data available in the EISS database for
the 2002–2003 winter (weeks 40/2002 to 20/2003) were
analysed. Data from both sentinel practitioners and other
sources (from hospitals, non-sentinel physicians, residen-
tial institutions) were used. Data from these other sources
are referred to as non-sentinel in this paper. Four coun-
tries were included: England, France, the Netherlands and
Scotland. Data for France was confined to nine regions in
the south covering 37.5% of the French population. The
selection of countries was based on the availability of
both sentinel and non-sentinel virological data on RSV
and influenza, and on a minimum number of 500 non-
sentinel respiratory specimens tested for RSV and/or influ-
enza during the study winter.
Specimen collection and analysis
Combined nose and/or throat swabs were obtained from
selected patients presenting to physicians in sentinel prac-
tices with influenza-like illness. In addition, general prac-
titioners in Scotland were requested to sample patients
with acute respiratory infections in the absence of influ-
enza-like illness. The respiratory specimens were trans-
ported to participating laboratories mainly by regular
mail [18]. Similar laboratory methods were used in three
out of four countries (Table 1); France used enzyme-
linked assays including ELISA (enzyme-linked immuno-
sorbent assay) instead of RT-PCR (reverse transcriptase
polymerase chain reaction) [19]. Although the sensitivity
of ELISA has been reported to be lower than RT-PCR,
ELISA is reliable for rapid laboratory diagnosis of influ-
enza in infants and young children; for older patients
application of virus isolation or RT-PCR is necessary [20].
Samples were defined positive for RSV or influenza when
at least one laboratory test yielded a positive result.
The sentinel networks in England and Scotland did not
apply a precise case definition for influenza-like illness.
The case definition used in France was: sudden onset of
Table 1: Laboratory methods used for RSV and influenza virus 
detection or isolation.
Methods used for RSV 
detection/isolation
Methods used for 
influenza virus 
detection/isolation
England RT-PCR, culture RT-PCR, culture
France ELFA, culture ELISA, culture
Netherlands RT-PCR, culture IF, RT-PCR, culture
Scotland RT-PCR (multiplex) RT-PCR (multiplex)
ELFA: enzyme-linked fluorescent assay (automated qualitative test)
ELISA: enzyme-linked immunosorbent assay
IF: immunofluorescence; this technique was not performed for 
sentinel samples
RT-PCR: reverse transcriptase polymerase chain reactionBMC Infectious Diseases 2006, 6:128 http://www.biomedcentral.com/1471-2334/6/128
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respiratory symptoms with infection context (fever, head-
aches), in the absence of other diagnosis. The case defini-
tion in the Netherlands contained the following criteria:
an acute onset of illness (prodromal stage ≤ 3–4 days),
and at least one of the symptoms: coughing, rhinitis, sore
throat, frontal headache, retrosternal pain, or myalgia
[21]. The selection of patients for swabbing was not based
on pre-established diagnostic criteria. In France many
samples were obtained from children because paediatri-
cians as well as general practitioners are included in the
surveillance network [22]. Virological test results from
sentinel practices were specified by age group (0 to 4, 5 to
14, 15 to 64, and over 65 years). Non-sentinel specimens
obtained from hospitals were mostly examined for one or
other and not both of the viruses.
Data analysis
We examined the timeliness of RSV data entry into the
EISS database by investigating whether data on RSV were
included in the EISS Weekly Electronic Bulletin and com-
pared this to the timeliness of influenza data. The Weekly
Electronic Bulletin is published on the EISS website each
Friday and reports the influenza activity for EISS member
countries collected during the previous week. More details
on the Weekly Electronic Bulletin can be found in the
technical note [23]. For the statistical analysis, the com-
parisons of percentages were performed using EpiTable in
Epi Info version 6.04d (January 2001). Statistical signifi-
cance was concluded if the p-value was < 0.05.
Results
Respiratory Syncytial Virus
RSV detections are summarized for each of the four coun-
tries in Table 2. For England RSV detections from sentinel
practices were common in all age groups, but especially in
young children aged 0–4 years with 40.8% (N = 49) test-
ing positive for RSV. The highest percentage RSV positive
specimens was reported for the 0–4 age group in Scotland
(10.3%, N = 29) and France (12.2%, N = 426) as well. In
the Netherlands, RSV was detected in one person aged
over 65 years. In England, the percentage of RSV positive
reports (26.7%) was higher than that for influenza
(21.3%; Chi2 = 3.9, p = 0.048). Non-sentinel data (availa-
ble by age for England and Scotland only) showed that
92% or more of the RSV positive reports were obtained in
children 0 to 4 years.
Influenza
Influenza virus detections are summarized in Table 3.
Sentinel data indicated more influenza reports than RSV
in Scotland, France and the Netherlands. The highest spec-
imen positive proportions of influenza viruses were
Table 2: RSV detections by country and age group for sentinel and non-sentinel specimens.
Sentinel Non-sentinel
Country Age group (years) Total number of 
specimens tested
Number of 
specimens tested 
positive for RSV
Percentage 
positive (%)
Number of 
specimens tested 
positive for RSV
England 0–4 49 20 40.8 3,982
5–14 63 16 25.4 13
15–64 307 77 25.1 60
> 65 45 13 28.9 11
NK 11 1 9.1 85
Total 475 127 26.7 4,151
Scotland 0–4 29 3 10.3 1,474
5–14 67 0 - 24
15–64 444 13 2.9 56
> 65 58 3 5.1 19
NK 15
Total 598 19 3.2 1,588
France 0–4 426 52 12.2
5–14 442 20 4.5
15–64 557 14 2.5
> 65 32 0 -
Total 1,457 86 5.9 1,748
Netherlands 0–4 0 - -
5–14 7 0 -
15–64 42 0 -
> 65 7 1 14.3
Total 56 1 1.8 1,757
NK: not knownBMC Infectious Diseases 2006, 6:128 http://www.biomedcentral.com/1471-2334/6/128
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reported in children aged 5–14 years (England 52.4%;
France 41.6%; Scotland 23.9%). Non-sentinel data (avail-
able by age for England and Scotland only) showed most
confirmed influenza cases in the 0–4 and 15–64 age
groups.
Timeliness
In each of the four countries sentinel and/or non-sentinel
RSV data were entered in a timely manner, within 1–2
weeks after specimen collection, into the EISS database. A
total of 26 Weekly Electronic Bulletins were published
during the 2002–2003 winter season, from week 42 to
week 15 of the following year. For the Netherlands, timely
RSV data were not available for weeks 42–50 because data
entry only started that season. For the four countries data
on influenza was reported for a total of 97 out of 104
weeks and RSV reports where made in a timely manner in
87 out of 104 weeks.
Discussion
We have assessed whether EISS could be used to build a
European RSV surveillance system. Surveillance systems
must be timely in order to be effective. The EISS system
has demonstrated timeliness in providing data on influ-
enza and as this report shows in four countries, timely
data on RSV. Sentinel data indicated that RSV contributed
considerably to influenza-like illness, especially in young
children. Since the infrastructure of EISS is well estab-
lished [24], we suggest the use of EISS as a model for set-
ting up an RSV surveillance system in Europe.
Healthcare based surveillance systems are dependent
upon persons consulting doctors. For common respira-
tory infections, there are many more infected persons in
the community who do not consult their doctor. Selection
biases which start with the decision to consult are com-
pounded at the point of consultation. In addition, sensi-
ble use of virological investigation does not necessarily
mean that every suspect case is investigated. Certainly as
far as patients in the community are concerned, routine
virological investigation for a common condition which is
usually minor is not economically justifiable. Further-
more, the patient's willingness to be sampled will always
be a major consideration.
The EISS differentiates between sentinel and non-sentinel
sources of data. Sentinel networks in Europe are chiefly
based on general practices (and in some European coun-
tries also on paediatric primary care services) and these are
essential to provide insight into what is happening in the
community at large. However, the hospital admission is a
useful proxy for severity of illness and it is desirable there-
Table 3: Influenza virus detections by country and age group for sentinel and non-sentinel specimens.
Sentinel Non-sentinel
Country Age group (years) Total number of 
specimens tested
Number of 
specimens tested 
positive for influenza
Percentage positive (%) Number of 
specimens tested 
positive for influenza
England 0–4 49 12 24.5 260
5–14 63 33 52.4 81
15–64 307 51 16.6 143
> 65 45 2 4.4 45
NK 11 3 27.3 12
Total 475 101 21.3 541
Scotland 0–4 29 0 0 64
5–14 67 16 23.9 53
15–64 444 13 2.9 108
> 65 58 2 3.4 31
NK 1
Total 598 31 5.2 257
France 0–4 426 82 19.2
5–14 442 184 41.6
15–64 557 109 19.6
> 65 32 1 3.1
Total 1,457 376 25.8 243
Netherlands 0–4 0 0
5–14 7 3 42.9
15–64 42 8 19.0
> 65 7 4 57.1
Total 56 15 26.8 239
NK: not knownBMC Infectious Diseases 2006, 6:128 http://www.biomedcentral.com/1471-2334/6/128
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fore to have access to additional hospital source data. This
is particularly important when an illness is common in all
age groups but hospital admission is much more likely in
particular age groups. Accordingly we wish to encourage
data collection from hospitals either on a routine basis
from all hospitals or perhaps more thought might be
given to the development of sentinel hospitals with a
higher level of commitment to high quality data capture
and more structured virological investigation.
Our study has shown that the age distribution of RSV pos-
itive cases was similar in the four countries. For England
relatively more RSV than influenza was reported but this
was not so in the other three countries. A possible reason
for this could be the use of a more sensitive diagnostic test
in England compared to the other countries. Within EISS
the need for harmonization of laboratory methods is rec-
ognised and a Community Network of Reference Labora-
tories has been established in 2003. This Network
encourages the harmonisation of laboratory methods for
the detection of influenza in EISS and assesses the quality
of laboratory testing for influenza and RSV [25].
To see whether the data for England were consistent with
earlier findings, we compared our results to data pub-
lished previously on RSV [10]. More RSV than influenza
virus was reported for one of the winter seasons (1997–
98), this finding is similar to what we have reported for
2002–2003. It is important to note that differences
between countries and seasons can simply be due to sea-
sonal variation; lower proportions of RSV detections from
patients with influenza-like illness have been observed for
England as well [26].
The sentinel networks in all four countries used combined
nose and/or throat swabs inserted in the same vial. These
have proved reliable for influenza surveillance [27]. How-
ever, the best site to collect material for viral detection
may differ between influenza virus and RSV. Nasal swabs
may be less specific than nasopharyngeal aspiration [28],
on the other hand swabs are probably less painful and
easier to obtain in a general practice setting. Facilities for
sampling patients in the hospital are generally better than
those in the community since there may be increased
opportunity for sample collection and less limitation on
sample transportation with hospitals linked directly to
microbiology laboratories.
The diagnosis made, the selection of patients for swab-
bing, the quality of the swab taken, the transport proce-
dures, the virological investigation methods and the
experience of the laboratory concerned, all influence virus
detection rates. The majority of sentinel respiratory speci-
mens did not test positive for either influenza or RSV. This
may be explained by other respiratory viruses that are
known to cause symptoms similar to influenza and RSV
infection [29,30] but few are regularly investigated. As an
example, for Scotland, 83 (13.9%) sentinel swabs tested
positive for picornavirus during the 2002–2003 winter
season. Furthermore, positivity rates differed considerably
between countries: e.g. in Scotland the percentage positive
for RSV and influenza was only 8%. In the future, the EISS
might implement more respiratory viruses for surveillance
purposes simultaneously after introducing RSV. Nine
countries in EISS already tested sentinel specimens for
more viruses than RSV and influenza in 2002, e.g. for
human metapneumovirus, rhinovirus, coronavirus, aden-
ovirus, C. pneumoniae or para-influenza virus.
Discrepancies in positivity rates could reflect several fac-
tors mentioned above; but it is also possible that payment
to general practitioners for taking swabs in Scotland leads
to sampling bias. In addition, general practitioners in
Scotland are requested to take samples from patients with
acute respiratory infections in the absence of influenza.
Relatively few respiratory specimens were collected by the
Dutch sentinel network which can lead to underestima-
tion of the incidence of RSV and influenza as judged from
virological data. This seems in particular true for children
and the elderly.
The current methodological differences between countries
and the constraints of the study (data for four countries
and one season) imposes limitations. Since we selected
and analysed data for the four countries that tested senti-
nel specimens during the 2002–2003 winter season for
RSV, we cannot state that all members of EISS are able to
comply to routine RSV reporting. However, this study
demonstrated that it is possible to report RSV in addition
to influenza. We believe our results pave the way for the
development of an RSV surveillance system running in
parallel to influenza surveillance.
Conclusion
Our conclusions relate to recommendations for an RSV
surveillance programme.
1. Specimens collected as part of an influenza surveillance
programme should also be tested for RSV.
2. Both combined nose/throat swabs and nasal pharyn-
geal aspirates are acceptable for RSV diagnosis.
3. The application of molecular techniques such as real
time PCR in the diagnosis of respiratory disease has been
demonstrated and we advocate this technique for RSV
detection.
4. We encourage further developments on the use of
standardized methods and laboratory techniques.BMC Infectious Diseases 2006, 6:128 http://www.biomedcentral.com/1471-2334/6/128
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5. The development of a sentinel approach of representa-
tive hospitals should be considered.
6. We recommend the new networks joining EISS to inte-
grate RSV surveillance alongside influenza.
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